Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754701 | 1.00 | HDAC2 (0.41) | HDAC2BACE1ACHEMEN1KMT2A | |
| SCHEMBL4667915 | 0.93 | BACE1 (0.43) | HDAC2BACE1ACHEMEN1KMT2A | |
| SCHEMBL4754382 | 0.93 | BACE1 (0.43) | HDAC2BACE1ACHEMEN1KMT2A | |
| SCHEMBL4015839 | 0.87 | MEN1 (0.44) | ACHEMEN1KMT2AHDAC4MEF2D | |
| SCHEMBL4670737 | 0.86 | HDAC4 (0.46) | HDAC2BACE1MEN1KMT2ADRD2 | |
| SCHEMBL4667914 | 0.86 | BACE1 (0.43) | BACE1ACHEMEN1KMT2AMAOB | |
| SCHEMBL4017819 | 0.84 | MEN1 (0.47) | HDAC2MEN1KMT2AHDAC3HDAC1 | |
| SCHEMBL4019849 | 0.83 | MEN1 (0.44) | HDAC2BACE1MEN1KMT2AHDAC3 | |
| SCHEMBL4014345 | 0.83 | MMP1 (0.48) | BACE1ACHEMEN1KMT2AMAOB | |
| SCHEMBL4015068 | 0.83 | MEN1 (0.44) | HDAC2MEN1KMT2AHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008152097-A1 | CINNAMIC ACID DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| EP-2003118-A1 | Cinnamic acid derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-17 | — | — | EP | claimed |
| WO-2008152097-A1 | CINNAMIC ACID DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152097-A1 | CINNAMIC ACID DERIVATIVES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
| EP-2003118-A1 | Cinnamic acid derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-17 | — | — | EP | disclosed |